46results about How to "Enhance anti-tumor immunity" patented technology

Provided is an IL-15 heterodimeric protein, such as an IL-15 / IL-15Rα heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15Rα or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.

The invention discloses a novel replicating oncolytic adenovirus capable of simultaneously inhibiting immune checkpoints of PD-L1 and TIGIT and application thereof. According to the novel replicatingoncolytic adenovirus capable of simultaneously inhibiting immune checkpoints of PD-L1 and TIGIT, a soluble fusion protein capable of simultaneously inhibiting immune checkpoints of PD-L1 and TIGIT andactivating immune costimulatory pathways is characterized in that both ends of the soluble fusion protein are a PD1 (programmed cell death protein 1) extracellular region for binding PD-L1 and a PVR(poliovirus receptor) extracellular region for binding TIGIT respectively, PD1 fragments and PVR fragments are connected through a linker sequence, and both ends of the soluble fusion protein can simultaneously inhibiting the immune checkpoints of PD-L1 and TIGIT after binding PD-L1 and TIGIT respectively. Experiments show that the novel replicating oncolytic adenovirus (ad5sPD1PVR) can significantly inhibit the immune checkpoints and activate antitumor immunity effects, achieve significant antitumor activity and accordingly have a good prospect and high values for developing antitumor drugs.

Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse / humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.

Described herein are compositions a genetically modified comprising nucleic acids encoding a chimeric antigen receptor (CAR) and a checkpoint inhibitor and methods for using the compositions to treatcancer.

The invention discloses an extracting process of cordyceps sinensis mycelium polysaccharide of a composite preparation for preventing a tumor, and the method comprises the following steps of: boiling 100 g of mycelium powder obtained by concentrating a cordyceps sinensis fermentation extracting solution; heating a filtering solution to obtain a concentrated solution; collecting the concentrated solution in a water bath so as to be concentrated; packaging the concentrated solution into eight centrifugal tubes so as to be centrifuged to obtain a water-soluble cordyceps sinensis polysaccharide solution; collecting liquid supernatant in the solution and slowly adding the liquid supernatant into absolute ethyl alcohol which is 4 times as much as the volume of the liquid supernatant; standing to obtain alcohol sediment; centrifuging and collecting alcohol precipitated polysaccharide in each centrifugal tube into each centrifugal tube; washing the alcohol precipitated polysaccharide twice by use of ethanol and freezing and drying in vacuum and at a low temperature to obtain a rough cordyceps sinensis mycelium polysaccharide; dissolving the rough cordyceps sinensis mycelium polysaccharide into distilled water and re-treating by suitable amount of the ethanol to obtain sediment; and freezing and drying the sediment in vacuum and at the low temperature to obtain cordyceps sinensis mycelium polysaccharide powder. The extracting process disclosed by the invention is used for finely sieving components in the rough polysaccharide to sieve components for accelerating anti-tumor immune cells to be multiplied, so that the anti-tumor immune effect of an organism is enhanced.

The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade treatment.

The present invention is directed to hybrid chimera antisense oligonucleotides including deoxyribonucleotide and 2′-deoxy-2′-fluoro-β-D-arabinonucleotide which binds to a Foxp3 mRNA, and to methods of use thereof. The methods include the use for reducing expression level of Foxp3 gene, increasing anti-tumor activity, and treating cancer in a subject.

The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.

The invention provides a tumor vaccine and a preparation method thereof. The tumor vaccine comprises dendritic cells which block signal pathways of CD44 and CD11b molecules. The invention further provides a method for preparing the tumor vaccine. The method includes the following steps: (1) acquiring mononuclear cells from peripheral blood or umbilical cord blood of a mammal, inducing the mononuclear cells into mature dendritic cells or acquiring bone marrow hematopoietic precursor cells from bone marrow of the mammal, and inducing the mononuclear cells into mature dendritic cells; (2) blocking the signal pathways of the CD44 and CD11b molecules of the mature dendritic cells; and (3) collecting the dendritic cells blocking the signal pathways of the CD44 and CD11b molecules. The tumor vaccine has a good anti-tumor effect, a wide anti-tumor spectrum and good use safety.

The invention provides a tumor vaccine and a preparation method thereof. The tumor vaccine comprises dendritic cells blocking CD44 molecular signal channels. The invention also provides the method forpreparing the tumor vaccine. The method comprises the steps that 1) single karyocytes are obtained from the peripheral blood or umbilical cord blood of a mammal to be induced into the mature dendritic cells, or medullary hematopoiesis precursor cells are obtained from the bone marrow of the mammal to be induced into the mature dendritic cells; 2) the CD44 molecular signal channels of the mature dendritic cells are blocked; 3) the mature dendritic cells blocking the CD44 molecular signal channels are collected. The tumor vaccine has good tumor resistance, a wide anti-tumor spectrum and good use safety.